KORMAN, N.; PAPP, K.; BAGEL, J. .; FOLEY, P.; MORITA, A.; BANERJEE, S.; COLSTON, E.; WANG, T.; THROUP, J.; THACI, D. Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Moderate to Severe Plaque Psoriasis: Onset of Action in the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 5, n. 6, p. s39, 2021. DOI: 10.25251/skin.5.supp.39. Disponível em: https://www.jofskin.org/index.php/skin/article/view/1390. Acesso em: 17 may. 2022.